Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
on Tenaya Therapeutics to $2 from $5 and kept an Overweight rating on the shares. In a sector outlook note, the firm predicted that the US small-to-mid cap biotech stocks will continue to outperform in 2026. This bullish view is driven by commercial-stage companies transitioning from capital consumers to producers and a looming patent cliff that is currently threatening the revenue of large-cap biopharma. Earlier on December 16, Canaccord Genuity recently lowered its price target for Tenaya Therapeutics to $4 from $6, while maintaining a Buy rating. This adjustment reflected the impact of a recent $60 million capital raise (completed in December 2025), which caused some shareholder dilution but extended the company's cash runway into mid-2027. On December 12, H.C. Wainwright also lowered its price target for Tenaya Therapeutics Inc. (NASDAQ:TNYA) to $3 from $5 while maintaining a Buy rating. This reduction was also primarily due to the share dilution resulting from the company's $
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease TherapeuticsGlobeNewswire
- Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026GlobeNewswire
- Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated MilestonesGlobeNewswire
TNYA
Earnings
- 11/10/25 - Beat
TNYA
Sec Filings
- 3/5/26 - Form 8-K
- 2/26/26 - Form SCHEDULE
- 2/26/26 - Form 4
- TNYA's page on the SEC website